Pri­vate eq­ui­ty firm taps ex-Ed­i­tas CEO Jim Mullen to help ex­pand phar­ma port­fo­lio — with a nod to cell, gene ther­a­pies

Jim Mullen is lend­ing his years of biotech CEO ex­pe­ri­ence — from Bio­gen, Patheon and Ed­i­tas — to the pri­vate eq­ui­ty firm Ad­vent In­ter­na­tion­al.

Ad­vent man­ag­ing part­ner John Mal­don­a­do said Mullen will help his team ex­pand their reach to phar­ma­ceu­ti­cal and phar­ma ser­vices com­pa­nies “across con­tract man­u­fac­tur­ing, com­mer­cial­iza­tion, and re­search.”

“Jim’s work at Ed­i­tas and Ther­mo Fish­er have put him at the fore­front of the cell and gene ther­a­py rev­o­lu­tion,” Carmine Petrone, man­ag­ing di­rec­tor at Ad­vent, added in a state­ment. “We are ex­cit­ed to part­ner with Jim as we con­tin­ue to look for trans­for­ma­tive com­pa­nies that are en­abling the de­vel­op­ment, man­u­fac­ture and com­mer­cial­iza­tion of these ad­vanced ther­a­pies.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER